Wells Fargo
CRSP icon

Wells Fargo’s CRISPR Therapeutics CRSP Stock Holding History

Wells Fargo’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
263,169
-17,540
-6% -$924K ﹤0.01% 1900
2026
Q1 		$13.4M Sell
280,709
-38,169
-12% -$2.01M ﹤0.01% 1814
2025
Q4 		$16.7M Buy
318,878
+15,700
+5% +$940K ﹤0.01% 1625
2025
Q3 		$19.6M Buy
303,178
+67,438
+29% +$3.87M ﹤0.01% 1476
2025
Q2 		$11.5M Sell
235,740
-29,786
-11% -$1.15M ﹤0.01% 1802
2025
Q1 		$9.04M Buy
265,526
+45,403
+21% +$1.92M ﹤0.01% 1942
2024
Q4 		$8.66M Buy
220,123
+17,094
+8% +$807K ﹤0.01% 1994
2024
Q3 		$9.54M Sell
203,029
-24,570
-11% -$1.25M ﹤0.01% 1869
2024
Q2 		$12.3M Buy
227,599
+11,205
+5% +$648K ﹤0.01% 1575
2024
Q1 		$14.7M Buy
216,394
+47,997
+29% +$3.44M ﹤0.01% 1439
2023
Q4 		$10.5M Sell
168,397
-34,841
-17% -$1.93M ﹤0.01% 1662
2023
Q3 		$9.22M Buy
203,238
+2,796
+1% +$144K ﹤0.01% 1617
2023
Q2 		$11.3M Sell
200,442
-6,153
-3% -$349K ﹤0.01% 1526
2023
Q1 		$9.34M Buy
206,595
+69,932
+51% +$3.4M ﹤0.01% 1653
2022
Q4 		$5.56M Sell
136,663
-2,989
-2% -$159K ﹤0.01% 2006
2022
Q3 		$9.13M Buy
139,652
+1,145
+0.8% +$83K ﹤0.01% 1584
2022
Q2 		$8.42M Sell
138,507
-57,380
-29% -$3.37M ﹤0.01% 1684
2022
Q1 		$12.3M Buy
195,887
+3,698
+2% +$232K ﹤0.01% 1671
2021
Q4 		$14.6M Sell
192,189
-270,651
-58% -$23.6M ﹤0.01% 1582
2021
Q3 		$51.8M Sell
462,840
-3,692
-0.8% -$464K 0.01% 1030
2021
Q2 		$75.5M Buy
466,532
+86,690
+23% +$10.5M 0.02% 822
2021
Q1 		$46.3M Sell
379,842
-84,676
-18% -$12.8M 0.01% 1087
2020
Q4 		$71.1M Sell
464,518
-96,142
-17% -$11.4M 0.02% 798
2020
Q3 		$46.9M Buy
560,660
+18,258
+3% +$1.62M 0.01% 904
2020
Q2 		$39.9M Buy
542,402
+40,883
+8% +$2.39M 0.01% 962
2020
Q1 		$21.3M Buy
501,519
+94,137
+23% +$4.86M 0.01% 1198
2019
Q4 		$24.8M Sell
407,382
-113,523
-22% -$6.2M 0.01% 1330
2019
Q3 		$21.4M Sell
520,905
-83,000
-14% -$3.97M 0.01% 1395
2019
Q2 		$28.4M Buy
603,905
+116,540
+24% +$4.66M 0.01% 1245
2019
Q1 		$17.4M Buy
487,365
+12,786
+3% +$442K 0.01% 1538
2018
Q4 		$13.6M Buy
474,579
+45,684
+11% +$1.59M ﹤0.01% 1647
2018
Q3 		$19M Buy
428,895
+65,238
+18% +$3.42M 0.01% 1535
2018
Q2 		$21.4M Sell
363,657
-97,720
-21% -$5.57M 0.01% 1448
2018
Q1 		$21.1M Buy
461,377
+439,860
+2,044% +$18.2M 0.01% 1417
2017
Q4 		$505K Buy
21,517
+3,165
+17% +$60.1K ﹤0.01% 4391
2017
Q3 		$328K Buy
18,352
+10,365
+130% +$188K ﹤0.01% 4614
2017
Q2 		$128K Buy
7,987
+6,560
+460% +$108K ﹤0.01% 5053
2017
Q1 		$31K Buy
1,427
+447
+46% +$8.78K ﹤0.01% 5598
2016
Q4 		$20K Buy
+980
New +$18.3K ﹤0.01% 5621

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's CRSP Position: Q2 2026 in Review

Wells Fargo reduced its CRISPR Therapeutics (CRSP) stake by 6.2% in Q2 2026, selling an estimated $924K and leaving 263,169 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Wells Fargo first reported a position in CRSP in Q4 2016 and has held it in 39 quarters since. The position peaked at $75.5M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Wells Fargo held 263,169 shares of CRISPR Therapeutics worth $14.4M as of Q2 2026.
  • Wells Fargo sold 17,540 CRISPR Therapeutics shares in Q2 2026, an estimated $924K.
  • CRISPR Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1900 holding.
  • Wells Fargo first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • Wells Fargo's CRISPR Therapeutics position peaked at $75.5M in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.